Equities Analysts Offer Predictions for IPA FY2028 Earnings

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Equities research analysts at HC Wainwright cut their FY2028 earnings estimates for shares of ImmunoPrecise Antibodies in a note issued to investors on Monday, March 31st. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.08 per share for the year, down from their previous forecast of $0.13. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ FY2029 earnings at $0.17 EPS.

ImmunoPrecise Antibodies (NASDAQ:IPA) last issued its earnings results on Friday, March 28th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. The company had revenue of $4.23 million during the quarter, compared to analysts’ expectations of $6.59 million.

Separately, Benchmark reiterated a “speculative buy” rating and issued a $3.00 target price on shares of ImmunoPrecise Antibodies in a report on Tuesday.

ImmunoPrecise Antibodies Trading Down 10.3 %

NASDAQ IPA opened at $0.34 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.85 and a debt-to-equity ratio of 0.36. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $1.48. The company has a market capitalization of $10.56 million, a PE ratio of -0.44 and a beta of 0.09. The stock has a 50-day simple moving average of $0.42 and a 200 day simple moving average of $0.47.

Institutional Trading of ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC lifted its holdings in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,558,892 shares of the company’s stock after purchasing an additional 263,451 shares during the quarter. Ingalls & Snyder LLC owned 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent SEC filing. 6.70% of the stock is currently owned by institutional investors and hedge funds.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.